证券代码：688276 证券简称：百克生物 公告编号：2023-040 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 10 月 18 日(星期三)至 10 月 23 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 10 月 24 日（星期二）上午 09:00-10:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 长春百克生物科技股份公司（以下简称"公司"）将于 2023 年 10 月 24 日发 布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况，公司计 ...

证券代码：688276 证券简称：百克生物 长春百克生物科技股份公司投资者关系活动记录表 编号：2023-011 特定对象调研 £分析师会议 £媒体采访 £业绩说明会 投资者关系活 £新闻发布会 £路演活动 动类别 £现场参观 £其他（请文字说明其他活动内容） 广发基金、国泰基金、高毅资产、高毅资产、富国基金、 参与单位名称 华安基金、长城基金唐、泓澄投资、中金资管、湘财基 及人员姓名 金、信达证券 时间 2023年9月20日10:00、15:00 ...

中信证券股份有限公司关于长春百克生物科技股份公司 2023年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为长春百克 生物科技股份公司（以下简称"百克生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券 交易所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引 第1号——规范运作》以及《科创板上市公司持续监管办法（试行）》、《上海 证券交易所上市公司自律监管指引第11号——持续督导》等相关规定，负责百克 生物上市后的持续督导工作，并出具本持续督导年度跟踪报告。 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 保荐机构已建立健全并有效执行了持续 | | 1 | 度，并针对具体的持续督导工作制定相 | 督导制度，并制定了相应的工作计划。 | | | 应的工作计划。 | | | | 根据中国证监会相关规定，在持续督导 | 保荐机构已与百克生物签订保荐协议， | | | 工作开始前，与上市公司签署持续督导 | | | 2 | ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2023 reached CNY 559.64 million, a 26.93% increase compared to CNY 440.92 million in the same period last year[16]. - Net profit attributable to shareholders was CNY 111.38 million, representing a 51.39% increase from CNY 73.57 million year-on-year[16]. - The basic earnings per share increased by 50.00% to CNY 0.27, while diluted earnings per share also rose by 50.00%[17]. - The company achieved a revenue of CNY 559.6443 million during the reporting period, reflecting a stable profit model supported by over 15 years of industrialized vaccine production experience[22]. - The company reported a total profit of ¥134,214,988.66 for the first half of 2023, compared to ¥101,065,362.05 in the same period of 2022, indicating an increase of approximately 33%[162]. - The total comprehensive income for the first half of 2023 was ¥123,109,617.20, compared to ¥92,101,526.02 in the first half of 2022, reflecting a growth of approximately 34%[162]. Research and Development - Research and development expenses increased by 30% to 100 million RMB, focusing on the development of new vaccines and biopharmaceuticals[1]. - Research and development expenses accounted for 17.51% of operating revenue, slightly down from 18.75% in the previous year[17]. - The company has a strong focus on vaccine research and development, with 116 specialized R&D personnel, of which over 84% hold a bachelor's degree or higher[20]. - The company is actively expanding its vaccine product line, including the varicella vaccine and the nasal spray influenza vaccine, which is the only one of its kind in China[20]. - The company has established five core technology platforms, including "viral large-scale culture technology platform" and "mRNA vaccine technology platform," which cover the entire process of vaccine R&D and commercialization[23]. - The company is focusing on developing mRNA vaccines for cancer treatment and infectious disease prevention, leveraging its technological advantages[30][38]. - The company has a pipeline of 13 vaccine candidates and 3 monoclonal antibodies for infectious disease prevention, indicating a strong product development pipeline[40]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[1]. - The company is expanding its international market presence, targeting new export countries and regions to increase sales share[46]. - A new vaccine product is expected to be launched in Q4 2023, which is anticipated to contribute an additional 50 million RMB in revenue[1]. - The marketing strategy for the shingles vaccine has been implemented across 25 provinces, enhancing market penetration[45]. Financial Position - The company has maintained a strong cash position of 200 million RMB, providing flexibility for future investments[1]. - The total assets of the company at the end of the reporting period were CNY 4.43 billion, a 3.34% increase from CNY 4.28 billion at the end of the previous year[16]. - The company reported a net cash flow from operating activities of CNY 74.47 million, a significant increase compared to the previous year's negative cash flow[60]. - The total expected investment for ongoing projects is ¥191,940,870.00, with cumulative investment reaching ¥71,754,900.00[36]. - The company made a significant equity investment of RMB 150 million in Chuanxin Biotechnology, increasing its stake to 17.64%[67]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces risks related to the rapid technological iteration in the biopharmaceutical industry, which could threaten its core technology platforms if R&D investments are not sustained[51]. - The company is at risk of new product sales not meeting expectations, particularly for its recently launched shingles vaccine, which requires time for market cultivation[58]. Corporate Governance - No significant changes in corporate governance or management structure were reported during this period[1]. - The company has established a multi-level talent development plan to enhance the skills of management and technical personnel, including the approval of a "Postdoctoral Research Workstation"[49]. - The company has committed to avoiding and minimizing related party transactions with Baike Biology, ensuring fair and reasonable pricing in any unavoidable transactions[111]. Environmental Responsibility - Environmental protection investments totaled ¥600,800 for the reporting period, reflecting the company's commitment to sustainability[79]. - The company has established an environmental protection mechanism and is classified as a key pollutant discharge unit[80]. - The company has received multiple environmental impact assessment approvals for various projects, including a rabies vaccine workshop renovation project[89].

证券代码：688276 证券简称：百克生物 公告编号：2023-029 长春百克生物科技股份公司 关于召开 2023 年半年度业绩说明会的公告 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 17 日（星期四）至 8 月 23 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司（以下简称"公司"）将于 2023 年 8 月 24 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果、财务状况，公司计划于 2023 年 8 月 24 日上午 09:00-10:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：20 ...

证券代码：688276 证券简称：百克生物 公告编号：2023-018 长春百克生物科技股份公司 关于参加网上集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 19 日（星期五）17：00 前访问 https://ir.p5w.net/zj/， 进入问题征集专题页面进行提问，公司将在说明会上对投资者普遍关注的问题进 行回答。 为进一步加强与投资者的互动交流，长春百克生物科技股份公司（以下简称 "公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司 共同举办的"2023 年吉林辖区上市公司网上集体业绩说明会"，现将有关事项公 告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景网 投资者关系互动平台"（http://ir.p5w.net）参与公 司业绩说明会，时间为 2023 年 5 月 22 日（星期一）14:30 至 16:00。 届时公司董事长马骥先生、董事、总经理孔维先生、董事会秘书张 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 179,431,529.21, representing a year-on-year increase of 30.21%[4] - The net profit attributable to shareholders for Q1 2023 was RMB 18,381,036.97, reflecting a growth of 6.15% compared to the same period last year[4] - The basic earnings per share for Q1 2023 were RMB 0.04, unchanged from the previous year[4] - The weighted average return on equity for Q1 2023 was 0.51%, a decrease of 0.05 percentage points compared to the previous year[4] - Total revenue for Q1 2023 reached ¥179,431,529.21, an increase of 30.2% compared to ¥137,800,487.71 in Q1 2022[16] - Net profit for Q1 2023 was ¥18,743,021.97, slightly up from ¥18,638,951.23 in Q1 2022, showing a marginal growth of 0.6%[16] - The net profit for Q1 2023 was CNY 18,381,036.97, an increase from CNY 17,316,309.23 in Q1 2022, representing a growth of approximately 6.2%[17] - The total comprehensive income for Q1 2023 was CNY 17,034,520.01, compared to CNY 16,030,710.69 in Q1 2022, indicating an increase of about 6.3%[17] - The net profit for Q1 2023 was CNY 27,700,652.65, slightly down from CNY 27,897,596.24 in Q1 2022, representing a decrease of 0.7%[24] Research and Development - Research and development expenses totaled RMB 40,993,593.68, which is an increase of 32.73% year-on-year, accounting for 22.85% of operating revenue[6] - R&D expenses in Q1 2023 amounted to ¥33,403,636.31, compared to ¥27,599,666.15 in Q1 2022, indicating a 21.1% increase[16] - Research and development expenses for Q1 2023 were CNY 33,403,636.31, up from CNY 27,599,666.15 in Q1 2022, reflecting a growth of 21.1%[23] Assets and Liabilities - The total assets at the end of Q1 2023 were RMB 4,216,091,144.74, a decrease of 1.57% from the end of the previous year[6] - Cash and cash equivalents decreased to ¥793,550,910.20 as of March 31, 2023, down from ¥866,543,101.94 at the end of 2022, a decline of 8.4%[12] - Accounts receivable decreased to ¥876,938,102.49 from ¥968,406,297.16, a reduction of 9.5%[12] - Inventory increased to ¥224,607,989.80 from ¥192,110,041.70, representing a growth of 16.9%[13] - Total assets as of March 31, 2023, were ¥4,216,091,144.74, a slight decrease from ¥4,283,551,750.23 at the end of 2022, down by 1.6%[14] - Total liabilities decreased to ¥629,153,586.92 from ¥724,015,550.19, a reduction of 13.1%[14] - The total assets as of Q1 2023 amounted to CNY 4,468,055,870.41, a decrease of 1.2% from CNY 4,524,486,571.41 in the previous year[22] - The total liabilities for Q1 2023 were CNY 612,482,582.03, down 13.2% from CNY 705,634,256.49 in Q1 2022[22] Cash Flow - The company reported a net cash flow from operating activities of RMB -4,585,538.96, which is not applicable for year-on-year comparison[4] - Cash inflow from operating activities in Q1 2023 was CNY 217,658,504.45, an increase of 23.0% compared to CNY 176,992,310.79 in Q1 2022[25] - The cash inflow from operating activities totaled CNY 217,664,822.46 in Q1 2023, compared to CNY 177,009,234.06 in Q1 2022, marking an increase of approximately 22.9%[18] - The cash outflow for operating activities was CNY 222,250,361.42 in Q1 2023, down from CNY 258,924,937.66 in Q1 2022, indicating a decrease of about 14.2%[18] - The company reported a decrease in cash paid to employees to CNY 50,291,436.66 in Q1 2023 from CNY 64,461,020.77 in Q1 2022, a reduction of approximately 22%[18] - The net cash flow from operating activities was -$16.89 million, an improvement from -$81.62 million in the previous period[27] - Total cash outflow from operating activities amounted to $234.55 million, down from $258.61 million year-over-year[27] Government Support and Future Plans - The company received government subsidies amounting to RMB 822,471.36 during the reporting period[7] - The company has received approval for the marketing authorization of its live attenuated varicella-zoster vaccine from the National Medical Products Administration[11] - The company is planning to issue Global Depository Receipts (GDRs) and list them on the Swiss Stock Exchange, backed by newly issued A-shares[11] Other Financial Metrics - The company’s total current assets were CNY 2,246,644,542.89 in Q1 2023, a slight decrease from CNY 2,338,251,177.59 in Q4 2022[20] - The company's total equity as of Q1 2023 was CNY 3,855,573,288.38, an increase of 1.0% from CNY 3,818,852,314.92 in Q1 2022[22] - The company reported a decrease in other comprehensive income, with a net amount of CNY -1,346,516.96 in Q1 2023 compared to CNY -1,285,598.54 in Q1 2022[24] - The company's cash paid for purchasing goods and services in Q1 2023 was CNY 27,694,777.69, significantly lower than CNY 64,930,206.82 in Q1 2022, indicating a decrease of 57.3%[25] - The total non-current assets as of Q1 2023 were CNY 2,221,411,327.52, a slight increase from CNY 2,186,235,393.82 in the previous year[22] - The impact of exchange rate changes on cash and cash equivalents was -$61,639.03, slightly better than -$70,944.11 previously[27] - The company did not apply new accounting standards for the current reporting period[28]

长春百克生物科技股份公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 27 日（星期四）上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 证券代码：688276 证券简称：百克生物 公告编号：2023-015 董事、常务副总经理：姜春来 董事会秘书：张喆 财务总监：孟昭峰 （如有特殊情况，参会人员可能进行调整） 四、 投资者参加方式 投资者可于 2023 年 4 月 20 日（星期四）至 4 月 26 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司（以下简称"公司"）已于 2023 年 4 ...

Financial Performance - Revenue for 2022 was RMB 1,071,446,025.21, a decrease of 10.86% compared to 2021[16] - Net profit attributable to shareholders was RMB 181,536,723.75, down 25.46% year-over-year[16] - Operating cash flow decreased by 71.62% to RMB 39,818,408.14[16] - Total assets increased by 2.61% to RMB 4,283,551,750.23[16] - Shareholders' equity grew by 4.15% to RMB 3,559,536,200.04[16] - Basic earnings per share dropped by 29.03% to RMB 0.44[17] - Weighted average ROE decreased by 4.11 percentage points to 5.21%[17] - The decline in performance was mainly due to market demand fluctuations affecting product sales[17] - Basic earnings per share, diluted earnings per share, and basic earnings per share after deducting non-recurring gains and losses decreased by 29.03%, 29.03%, and 33.33% respectively, mainly due to the decline in net profit for the year[18] - Operating income for Q1, Q2, Q3, and Q4 were 137.8 million yuan, 303.12 million yuan, 424.8 million yuan, and 205.73 million yuan respectively[20] - Net profit attributable to shareholders of the listed company for Q1, Q2, Q3, and Q4 were 17.32 million yuan, 56.26 million yuan, 138.25 million yuan, and -30.28 million yuan respectively[20] - Non-recurring gains and losses for 2022 amounted to 14.78 million yuan, including government subsidies of 18.57 million yuan[21][22] - The company's total operating income for 2022 was 1.07 billion yuan, a decrease of 130.58 million yuan or 10.86% compared to the previous year[25] - Net profit attributable to shareholders of the parent company was 181.54 million yuan, a decrease of 62.02 million yuan or 25.46% compared to the previous year[25] - The company incurred a provision for inventory impairment of 60.17 million yuan for nasal spray influenza vaccines and 2.25 million yuan for contract performance costs, totaling 62.43 million yuan[26] - The company disposed of nasal spray devices and other raw materials nearing expiration, resulting in a loss of 23.36 million yuan[26] - Gross profit margin for the main business was 87.19%, a decrease of 1.11 percentage points year-over-year[68] - Sales of varicella vaccine were 7.77 million doses, a decrease of 4.27% year-over-year[71] - Sales of nasal spray influenza vaccine were 387,200 doses, a decrease of 35.85% year-over-year[71] - Total liabilities at the end of 2022 were RMB 724.02 million, a decrease of 4.36% compared to the beginning of the year[65] - R&D expenses were RMB 133.53 million, a decrease of 14.82% year-over-year[67] - Net cash flow from operating activities was RMB 39.82 million, a decrease of 71.62% year-over-year[67] - Net cash flow from financing activities was RMB -41.28 million, a decrease of 102.94% year-over-year[67] - Direct material costs decreased by 10.10% to 33,574,583.11 yuan, accounting for 24.47% of total costs[72] - Manufacturing expenses increased by 19.93% to 52,917,498.05 yuan, accounting for 38.57% of total costs[72] - Transportation and storage costs decreased by 23.87% to 30,519,110.90 yuan, accounting for 22.24% of total costs[72] - Total costs for varicella vaccine decreased by 1.61% to 28,598,491.55 yuan, accounting for 20.84% of total costs[73] - Manufacturing expenses for nasal spray flu vaccine increased by 58.75% to 12,758,366.18 yuan, accounting for 9.30% of total costs[73] - Management expenses increased by 33.29% to 144,471,039.87 yuan due to personnel and salary adjustments[80] - Cash flow from operating activities decreased by 71.62% to 39,818,408.14 yuan due to reduced sales collections[82] - Cash flow from financing activities decreased by 102.94% to -41,284,069.80 yuan due to the absence of fundraising activities compared to the previous year[84] - Prepayments increased by 50.63% to RMB 27,250,172.66, mainly due to increased prepaid R&D service fees[85] - Other receivables increased by 104.82% to RMB 2,907,554.92, primarily due to increased freight advances[85] - Long-term deferred expenses surged by 972.56% to RMB 32,637,941.06, mainly due to the transfer of validation costs for the relocation of the varicella packaging workshop[85] - Deferred tax assets increased by 69.74% to RMB 54,197,208.96, driven by increased deductible temporary differences from inventory impairment provisions[85] - Accounts payable decreased by 61.19% to RMB 24,802,342.50, mainly due to payments for procurement[85] - Taxes payable increased by 128.57% to RMB 9,845,002.13, primarily due to an increase in corporate income tax payable[85] - Other current liabilities rose by 101.09% to RMB 138,702,869.17, mainly due to increased expected returns of influenza vaccines[85] - Total investment for the reporting period was RMB 132,120,104.68, a 0.26% increase from the previous year[107] - The cumulative fair value change of financial assets measured at fair value was RMB -6,130,445.56[108] - The ending balance of other equity instrument investments was RMB 33,238,398.53[109] - Huikang Biotech, a wholly-owned subsidiary, reported a net loss of 40.7846 million yuan with zero revenue and negative net assets of 341.6478 million yuan[111] - Ruizhou Biotech, a 10% equity investment, reported a net loss of 48.2435 million yuan with revenue of 708,000 yuan and net assets of 119.6356 million yuan[111] - Ningbo Chunpai, a 33.62% equity investment, reported a net profit of 1.2369 million yuan with revenue of 12.3663 million yuan and net assets of 66.3968 million yuan[111] - The company's revenue for 2022 reached $96.77 billion, marking a significant milestone in its financial performance[133] - The company achieved a 15% year-over-year growth in user base, reaching 500 million active users globally[133] - The company's net profit margin improved by 5 percentage points to 25% in 2022, driven by cost optimization and operational efficiency[133] - The company launched three new products in 2022, contributing $500 million to its annual revenue[133] - The company provided a positive outlook for 2023, projecting a revenue growth of 10-15% and a net profit margin of 26-28%[133] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares, totaling 61,926,104.70 yuan, which accounts for 34.11% of the net profit attributable to shareholders in 2022[3] - 2022 cash dividend proposal: RMB 1.50 per 10 shares, totaling RMB 61,926,104.70, accounting for 34.11% of the net profit attributable to shareholders[155][157] - 2021 cash dividend: RMB 1.00 per 10 shares, totaling RMB 41,284,069.80, accounting for 16.95% of the net profit attributable to shareholders[155] R&D and Innovation - R&D expenditure accounted for 14.54% of revenue, down 1.49 percentage points[17] - R&D investment reached 155.77 million yuan, accounting for 14.54% of revenue[27] - The company completed Phase I and II clinical trials for the liquid nasal spray influenza vaccine[27] - The company's shingles vaccine obtained the "Drug Registration Certificate"[27] - The company completed Phase I clinical trials for the DTaP vaccine (three-component) and is preparing for Phase III clinical samples[27] - The company's rabies monoclonal antibody entered the clinical trial stage[27] - The company has 13 vaccine projects and 2 monoclonal antibody projects in the pipeline, with key projects like DTaP vaccine, liquid nasal spray influenza vaccine, and rabies monoclonal antibody in clinical trials[31] - The company has established four core technology platforms: virus large-scale culture, formulation and adjuvant, genetic engineering, and bacterial vaccine technology platforms[38] - The virus large-scale culture technology platform has enabled the development and market approval of the varicella vaccine and the herpes zoster vaccine[39] - The formulation and adjuvant technology platform has led to the development of a 36-month shelf-life varicella vaccine and is advancing liquid formulations for nasal spray flu vaccines[40] - The genetic engineering technology platform is being used to develop vaccines and monoclonal antibodies for diseases such as Alzheimer's, rabies, and tetanus[41] - The company's bacterial vaccine technology platform includes large-scale bacterial fermentation, polysaccharide-protein conjugation, and purification techniques, with ongoing R&D for acellular pertussis-diphtheria-tetanus (three-component) combined vaccine and Haemophilus influenzae type b conjugate vaccine[42] - The company obtained 6 new invention patents during the reporting period, bringing the total number of invention patents to 42[43] - Total R&D investment in 2022 was RMB 155.77 million, a decrease of 19.16% year-over-year, with R&D investment accounting for 14.54% of operating revenue[45] - The company has 8 major R&D projects with cumulative investments exceeding RMB 500 million, including a pertussis-diphtheria-tetanus vaccine (RMB 100.09 million invested) and a zoster vaccine (RMB 181.97 million invested)[46] - The company has 132 R&D personnel, accounting for 10.54% of total employees, with an average annual salary of RMB 148,200[48] - The company has technical collaborations with Jilin University, Chinese Academy of Medical Sciences, and international partners like Intravacc[50] - The company's varicella vaccine maintains a leading market share, and the intranasal flu vaccine, the only approved live attenuated flu vaccine in China, was launched in the second half of 2020[51] - The company has a robust R&D pipeline with 13 vaccine candidates and 2 monoclonal antibodies for infectious disease prevention, including a pertussis-diphtheria-tetanus vaccine (three-component) leading in domestic development[51] - The company has completed Phase I and II clinical trials for its liquid intranasal flu vaccine, addressing stability issues and expanding the target population[51] - R&D investment in the reporting period was RMB 155.77 million, accounting for 14.54% of revenue[91] - The company obtained production approval for the herpes zoster vaccine in January 2023[91] - The liquid nasal spray influenza vaccine completed Phase I and II clinical trials[91] - R&D investment for the year reached RMB 75,388.88 thousand, accounting for 21.77% of revenue and 8.89% of net assets[98] - R&D expenditure for the bivalent pertussis vaccine (three-component) decreased by 38.95% to RMB 1,182.38 thousand[99] - R&D expenditure for the zoster vaccine decreased by 38.08% to RMB 2,224.33 thousand[99] - R&D expenditure for the influenza virus split vaccine (BK-01 adjuvant) increased by 110.72% to RMB 606.55 thousand[99] - R&D expenditure for the fully human anti-rabies virus monoclonal antibody decreased by 75.56% to RMB 1,507.64 thousand[99] - The company's R&D expenditure increased by 10% to $1.2 billion, focusing on AI and biotechnology innovations[133] Corporate Governance and Leadership - The company has no instances of non-operational fund occupation by controlling shareholders or related parties[4] - The company has no violations in decision-making procedures for external guarantees[5] - The company has no instances where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[5] - The company's 2022 annual report has been audited by Da Xin Certified Public Accountants, who issued a standard unqualified audit report[3] - The company's 2022 annual report includes forward-looking statements regarding future plans and development strategies, which do not constitute a substantive commitment to investors[4] - The company's 2022 annual report includes a detailed list of major shareholders and shareholding changes[6] - The company's board of directors has established four specialized committees: Strategy Committee, Nomination Committee, Audit Committee, and Compensation and Evaluation Committee[121] - The company has appointed 3 independent directors to enhance the objectivity, scientificity, and fairness of board decisions[121] - The company's chairman, Ma Ji, holds 0 shares and received 0 RMB in pre-tax compensation during the reporting period[128] - Kong Wei, the company's director, general manager, and core technical personnel, holds 10,426.06 million shares and received 1.2144 million RMB in pre-tax compensation[128] - Jiang Chunlai, the company's director, executive vice president, and core technical personnel, increased his shareholding by 1.2399 million shares during the reporting period[128] - Feng Daqiang, the chairman of the supervisory board, increased his shareholding by 1.3318 million shares during the reporting period[128] - Wei Wei, the company's vice president and core technical personnel, increased her shareholding by 1.1022 million shares during the reporting period[128] - The company's independent directors each received 72,000 RMB in pre-tax compensation during the reporting period[128] - The company's financial director, Meng Zhaofeng, received 822,700 RMB in pre-tax compensation during the reporting period[128] - Total company shares held by key personnel amount to 10,453.76 million, with a total value of 11,096.70 million, resulting in a net increase of 642.94 million[130] - Key personnel, including Yu Bing, Liu Dawei, and Zhu Changlin, transitioned from indirect to direct shareholding due to the dissolution of Daohe Biotechnology[130] - Ma Ji serves as the Chairman and Party Secretary of Changchun High-Tech Industry (Group) Co., Ltd., with extensive experience in various leadership roles since 1986[131] - Jiang Yuntao is the current Director and General Manager of Changchun High-Tech Industry (Group) Co., Ltd., with a career spanning from 1997 to present[131] - Li Xiufeng holds the position of Vice President at Changchun High-Tech Industry (Group) Co., Ltd., with a background in various managerial roles since 2019[131] - Zhu Xinggong is the Vice President and CFO of Changchun High-Tech Industry (Group) Co., Ltd., with prior experience in financial roles at Jilin Huakang Pharmaceutical Co., Ltd.[131] - Company Chairman Ma Ji indirectly holds 21,900 shares of the company through Changchun High-Tech[136] - Director Jiang Yuntao indirectly holds 20,100 shares of the company through Changchun High-Tech[136] - Director Li Xiufeng indirectly holds 25,300 shares of the company through Changchun High-Tech[136] - Director Zhu Xinggong indirectly holds 25,100 shares of the company through Changchun High-Tech[136] - Supervisor Zhang Deshen indirectly holds 23,200 shares of the company through Changchun High-Tech[136] - Chairman Ma Ji serves as Chairman of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Director Jiang Yuntao serves as Director and General Manager of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Director Li Xiufeng serves as Vice President of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Director Zhu Xinggong serves as Vice President and CFO of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Supervisor Zhang Deshen serves as Board Secretary and Chief Legal Officer of Changchun High-Tech from June 23, 2021, to June 22, 2024[137] - Total compensation for directors, supervisors, and senior management at the end of the reporting period was RMB 6.7829 million[140] - Total compensation for core technical personnel at the end of the reporting period was RMB 5.0867 million[140] - The company's Board of Directors approved the 2021 annual financial report and the 2022 financial budget report during the fifth board meeting[142] - The company's Board of Directors approved the 2021 profit distribution plan during the fifth board meeting[142] - The company's Board of Directors approved the signing of a contract for the development of a recombinant zoster vaccine (CHO cell) during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual report and its summary during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual board work report during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual asset impairment provision during the fifth board meeting[142] - The company's Board of Directors approved the 2021 annual financial report during the fifth board meeting[142] - The company's Board of Directors approved the 2022 financial budget report during the fifth board meeting[142] - The company held a total of 10 board meetings in 2022, with 8 conducted via a combination of on-site and teleconference methods, and 2 via teleconference only[145] - The Audit Committee held 5 meetings in 2022, reviewing key reports including the 2021 Annual Report, 2022 Q1 Report, 202

证券代码：688276 证券简称：百克生物 公告编号： 2023-008 长春百克生物科技股份公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 3 月 30 日（星期四）上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 3 月 23 日（星期四）至 3 月 29 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司（以下简称"公司"）将于 2023 年 3 月 30 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年年度 经营成果、财务状况，公司计划 ...